To include your compound in the COVID-19 Resource Center, submit it here.

FDA approves Alexion's Soliris for myasthenia gravis

FDA approved an sBLA for Soliris eculizumab from Alexion Pharmaceuticals Inc. (NASDAQ:ALXN) to treat refractory generalized myasthenia gravis in

Read the full 197 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE